PLGA microparticles encapsulating prostaglandin E 1- hydroxypropyl-β-cyclodextrin (PGE 1-HPβCD) complex for the treatment of Pulmonary Arterial Hypertension (PAH)

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1733-1749

  Gupta, Vivek ^a   Davis, Marauo ^b   Hope Weeks, Louisa J ^b   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

2 hydroxypropyl cyclodextrin; microparticles.; poly (lactic co glycolic acid); prostaglandin E 1; pulmonary arterial hypertension; pulmonary delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; POLYGLACTIN; PROSTAGLANDIN E1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; HEMODYNAMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE MICROPARTICLE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

ALPROSTADIL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BETA-CYCLODEXTRINS; CELL LINE; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTENSION, PULMONARY; INFUSION PUMPS; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79959871129     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0409-6     Document Type: Article

References (51)

1. F Hirayama K Uekama 1999 Cyclodextrin-based controlled drug release system Adv Drug Deliv Rev 36 125 41 10837712 10.1016/S0169-409X(98)00058-1 1:CAS:528:DyaK1MXksFensw%3D%3D (Pubitemid 29074480)
2. T Irie K Uekama 1997 Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J Pharm Sci 86 147 62 9040088 10.1021/js960213f 1:CAS:528:DyaK2sXhtVOgsLY%3D Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation (Pubitemid 27078377)
3. VJ Stella Q He 2008 Cyclodextrins Toxicol Pathol 36 30 42 18337219 10.1177/0192623307310945 1:CAS:528:DC%2BD1cXkslKgsL4%3D
4. S Gould RC Scott 2005 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review Food Chem Toxicol 43 1451 9 16018907 10.1016/j.fct.2005.03.007 1:CAS:528:DC%2BD2MXmt1eiu78%3D (Pubitemid 40961909)
5. M Jug M Becirevic-Lacan 2008 Development of a cyclodextrin-based nasal delivery system for lorazepam Drug Dev Ind Pharm 34 817 26 18622800 10.1080/03639040801926063 1:CAS:528:DC%2BD1cXptlaitLc%3D
6. TO Carpenter A Gerloczy J Pitha 1995 Safety of parenteral hydroxypropyl beta-cyclodextrin J Pharm Sci 84 222 5 7738806 10.1002/jps.2600840220 1:CAS:528:DyaK2MXjtl2nsL0%3D
7. J Kloeze 1969 Relationship between chemical structure and platelet-aggregation activity of prostaglandins Biochim Biophys Acta 187 285 92 4981666 1:CAS:528:DyaE3cXjvFQ%3D
8. BG Sood V Delaney-Black JV Aranda S Shankaran 2004 Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial Pediatr Res 56 579 85 15295081 10.1203/01.PDR.0000139927.86617.B6 1:CAS:528:DC%2BD2cXnsFGqsbs%3D (Pubitemid 39280911)
9. JL Wallace 1992 Prostaglandins, NSAIDs, and cytoprotection Gastroenterol Clin North Am 21 631 41 1516961 1:STN:280:DyaK38zoslOktg%3D%3D
10. Della Rocca G, Coccia C, Pompei L, Costa MG, Di Marco P, Pietropaoli P. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol. 2008;74:627-633.
11. R Igarashi M Takenaga J Takeuchi A Kitagawa K Matsumoto Y Mizushima 2001 Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting J Control Release 71 157 64 11274747 10.1016/S0168-3659(00)00373-4 1:CAS:528:DC%2BD3MXitFyrtbc%3D (Pubitemid 32234376)
12. K Nakazawa T Uchida Y Matsuzawa K Yokoyama K Makita K Amaha 1998 Treatment of pulmonary hypertension and hypoxia due to oleic acid induced lung injury with intratracheal prostaglandin E1 during partial liquid ventilation Anesthesiology 89 686 92 9743406 10.1097/00000542-199809000-00019 1:CAS:528:DyaK1cXmt1GktLs%3D (Pubitemid 28423967)
13. F Sakuma M Miyata R Kasukawa 1999 Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats Lung 177 77 88 9929405 10.1007/PL00007632 1:CAS:528:DyaK1MXhsFSjsbk%3D
14. FG Gu FD Cui YL Gao 2005 Preparation of prostaglandin E1-hydroxypropyl-beta-cyclodextrin complex and its nasal delivery in rats Int J Pharm 290 101 8 15664135 10.1016/j.ijpharm.2004.11.021 1:CAS:528: DC%2BD2MXkvVSluw%3D%3D (Pubitemid 40139049)
15. K Uekama Y Hieda F Hirayama H Arima M Sudoh A Yagi H Terashima 2001 Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue Pharm Res 18 1578 85 11758766 10.1023/A:1013034615464 1:CAS:528:DC%2BD3MXos1ejsrw%3D (Pubitemid 33022414)
16. M Wiese HP Cordes H Chi JK Seydel T Backensfeld BW Muller 1991 Interaction of prostaglandin E1 with alpha-cyclodextrin in aqueous systems: stability of the inclusion complex J Pharm Sci 80 153 6 2051319 10.1002/jps.2600800213 1:CAS:528:DyaK3MXhslWitrg%3D
17. M Yamamoto F Hirayama K Uekama 1992 Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation Chem Pharm Bull Tokyo 40 747 51 1611688 1:CAS:528:DyaK38Xktlems7Y%3D
18. J Meyer G Theilmeier H Van Aken HG Bone H Busse R Waurick F Hinder M Booke 1998 Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure Anesth Analg 86 753 8 9539597 1:CAS:528: DyaK1cXisFOqsbc%3D (Pubitemid 28177727)
19. V Gupta A Rawat F Ahsan 2010 Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J Pharm Sci 99 1774 89 19894275 1:CAS:528:DC%2BC3cXht12gsLg%3D
20. E Marttin JC Verhoef FW Merkus 1998 Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs J Drug Target 6 17 36 9769018 10.3109/10611869808997878 1:CAS:528:DyaK1cXms1ynu70%3D (Pubitemid 28499586)
21. T Yang A Hussain J Paulson TJ Abbruscato F Ahsan 2004 Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies Pharm Res 21 1127 36 15290851 10.1023/B:PHAM.0000032998.84488.7a 1:CAS:528:DC%2BD2cXltF2gt78%3D (Pubitemid 38954196)
22. DC Bibby NM Davies IG Tucker 2000 Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems Int J Pharm 197 1 11 10704788 10.1016/S0378-5173(00)00335-5 1:CAS:528:DC%2BD3cXhtl2qtbo%3D (Pubitemid 30125772)
23. G De Rosa D Larobina M Immacolata La Rotonda P Musto F Quaglia F Ungaro 2005 How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-beta-cyclodextrin system J Control Release 102 71 83 15653135 10.1016/j.jconrel.2004.09.030 (Pubitemid 40093777)
24. A Rawat QH Majumder F Ahsan 2008 Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J Control Release 128 224 32 18471921 10.1016/j.jconrel.2008.03.013 1:CAS:528:DC%2BD1cXmvVCrs7w%3D
25. F Ungaro R d'Emmanuele di Villa Bianca C Giovino A Miro R Sorrentino F Quaglia MI La Rotonda 2009 Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J Control Release. 135 25 34 19154761 10.1016/j.jconrel.2008.12.011 1:CAS:528:DC%2BD1MXjtFejurs%3D
26. Gonda I. Physico-chemical principles in aerosol delivery. In D J A Crommelinand K.K. Midha (eds.), Topics in Pharmaceutical Sciences, Medpharm GmbH Scientific Publisher, Stuttgart, 1991, pp. 95-115.
27. Y Yang N Bajaj P Xu K Ohn MD Tsifansky Y Yeo 2009 Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 1947 53 19135245 10.1016/j.biomaterials.2008.12.044 1:CAS:528: DC%2BD1MXhvFahsbw%3D
28. SK Gill AM Shobe LJ Hope-Weeks 2009 Synthesis of cobalt oxide aerogels and nanocomposite systems containing single-walled carbon nanotubes Scanning 31 132 8 19452519 10.1002/sca.20147 1:CAS:528:DC%2BD1MXhtVWjtL%2FL
29. OR Moss 1979 Simulants of lung interstitial fluid Health Phys 36 447 8 489300 1:CAS:528:DyaE1MXltF2lsL0%3D (Pubitemid 9218628)
30. A Hussain QH Majumder F Ahsan 2006 Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides Pharm Res 23 138 47 16320001 10.1007/s11095-005-8926- 9 1:CAS:528:DC%2BD28Xht1Cltro%3D (Pubitemid 43214670)
31. C Thomas A Rawat S Bai F Ahsan 2008 Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside J Pharm Sci 97 1213 23 17828746 10.1002/jps.21069 1:CAS:528:DC%2BD1cXivFenurw%3D
32. AL Nieminen GJ Gores JM Bond R Imberti B Herman JJ Lemasters 1992 A novel cytotoxicity screening assay using a multiwell fluorescence scanner Toxicol Appl Pharmacol 115 147 55 1641848 10.1016/0041-008X(92)90317-L 1:CAS:528:DyaK38XltVentbw%3D
33. T Qian AL Nieminen B Herman JJ Lemasters 1997 Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes Am J Physiol 273 C1783 92 9435481 1:CAS:528:DyaK1cXjvFSgsQ%3D%3D
34. TA Sarafian S Kouyoumjian D Tashkin MD Roth 2002 Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole Toxicol Lett 133 171 9 12119125 10.1016/S0378-4274(02)00134-0 1:CAS:528:DC%2BD38Xlt1Okt7o%3D (Pubitemid 34761974)
35. EA Zannou WH Streng VJ Stella 2001 Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins Pharm Res 18 1226 31 11587496 10.1023/A:1010947631380 1:CAS:528:DC%2BD3MXnt1ektLo%3D (Pubitemid 32900410)
36. KF Pistel T Kissel 2000 Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique J Microencapsul 17 467 83 10898087 10.1080/026520400405723 1:CAS:528: DC%2BD3cXkslOqu78%3D (Pubitemid 30420829)
37. C Srinivasan YK Katare T Muthukumaran AK Panda 2005 Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles J Microencapsul 22 127 38 16019899 10.1080/02652040400026400 1:CAS:528:DC%2BD2MXksVaiurc%3D (Pubitemid 40775302)
38. SC Lee JT Oh MH Jang SI Chung 1999 Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration J Control Release 59 123 32 10332048 10.1016/S0168-3659(98)00185-0 1:CAS:528:DyaK1MXjtVyktbw%3D (Pubitemid 29199919)
39. MS Hassan R Lau 2010 Feasibility study of pollen-shape drug carriers in dry powder inhalation J Pharm Sci 99 1309 21 19862802 1:CAS:528: DC%2BC3cXmvVGjtA%3D%3D
40. DA Edwards J Hanes G Caponetti J Hrkach A Ben-Jebria ML Eskew J Mintzes D Deaver N Lotan R Langer 1997 Large porous particles for pulmonary drug delivery Science 276 1868 71 9188534 10.1126/science.276.5320.1868 1:CAS:528: DyaK2sXksVCmsr4%3D (Pubitemid 27443665)
41. YI Jeong JG Song SS Kang HH Ryu YH Lee C Choi BA Shin KK Kim KY Ahn S Jung 2003 Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid Int J Pharm 259 79 91 12787638 10.1016/S0378-5173(03)00207-2 1:CAS:528:DC%2BD3sXktF2rtrg%3D (Pubitemid 36638556)
42. F Ungaro G De Rosa A Miro F Quaglia MI La Rotonda 2006 Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs Eur J Pharm Sci 28 423 32 16806857 10.1016/j.ejps.2006.05.005 1:CAS:528:DC%2BD28XntFWrtbw%3D (Pubitemid 44038350)
43. R Jeyanthi RC Mehta BC Thanoo PP DeLuca 1997 Effect of processing parameters on the properties of peptide-containing PLGA microspheres J Microencapsul 14 163 74 9132468 10.3109/02652049709015330 1:CAS:528: DyaK2sXht1ykur4%3D (Pubitemid 27095967)
44. MS Shive JM Anderson 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres Adv Drug Deliv Rev 28 5 24 10837562 10.1016/S0169-409X(97) 00048-3 (Pubitemid 27497671)
45. J Nakano AV Prancan NH Morsy 1973 Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat Jpn J Pharmacol 23 355 61 4541949 10.1254/jjp.23.355 1:CAS:528:DyaE3sXlt1ajsL0%3D
46. P Ney M Braun C Szymanski L Bruch K Schror 1991 Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)-an in vivo metabolite of PGE1 in man Eicosanoids 4 177 84 1663381 1:CAS:528: DyaK38XpvF2ktA%3D%3D
47. RF Henderson EG Damon TR Henderson 1978 Early damage indicators in the the lung I. Lactate dehydrogenase activity in the airways Toxicol Appl Pharmacol 44 291 7 675703 10.1016/0041-008X(78)90191-6 1:CAS:528:DyaE1MXht1al (Pubitemid 8365677)
48. A Hussain F Ahsan 2005 State of insulin self-association does not affect its absorption from the pulmonary route Eur J Pharm Sci 25 289 98 15911225 1:CAS:528:DC%2BD2MXks1Gitrc%3D (Pubitemid 40725059)
49. BD Beck JD Brain DE Bohannon 1982 An in vivo hamster bioassay to assess the toxicity of particulates for the lungs Toxicol Appl Pharmacol 66 9 29 6925426 10.1016/0041-008X(82)90057-6 1:CAS:528:DyaL3sXkvVWrsg%3D%3D (Pubitemid 13202176)
50. Y Matsukawa VH Lee ED Crandall KJ Kim 1997 Size-dependent dextran transport across rat alveolar epithelial cell monolayers J Pharm Sci 86 305 9 9050797 10.1021/js960352x 1:CAS:528:DyaK2sXhtVCqtbk%3D (Pubitemid 27113763)
51. L Matilainen T Toropainen H Vihola J Hirvonen T Jarvinen P Jarho K Jarvinen 2008 In vitro toxicity and permeation of cyclodextrins in Calu-3 cells J Control Release 126 10 6 18160169 10.1016/j.jconrel.2007.11.003 1:CAS:528:DC%2BD1cXhtlGjt7s%3D